English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -83.04%
Price change 2019 → 2020: 513.49%
Price change 2020 → 2021: -73.46%
Price change 2021 → 2022: -64.65%
Price change 2022 → 2023: -36.00%
Price change 2023 → 2024: -48.39%
Price change 2024 → 2025: 270.24%
Price change 2025 → 2026: 51.64%
Price change 2026 (year to date): 42.95%
Financial growth
Revenue CAGR (8 years): -100.00%
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 1.45
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -14.93
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 29.30% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ALTHX.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| THX Pharma | – | 1.45 | – | 🔒 |
| Fermentalg | – | 0.20 | +38.5 % | – |
| Adocia S.A. | – | 5.97 | +18.8 % | – |
| Klea Holding | 14.0 | 0.20 | +5.2 % | – |
| Novacyt S.A. | – | 0.45 | +28.1 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by THX Pharma over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2019 | 628,615 | -6.2 m | -989.6 % | n/a |
| 2020 | 328,448 | -5.3 m | -1,628.5 % | -47.8 % |
| 2021 | 671 | -9.1 m | -1,353,889.4 % | -99.8 % |
| 2022 | 462,553 | -7.3 m | -1,582.8 % | +68,834.9 % |
| 2023 | 330,368 | -7.6 m | -2,304.2 % | -28.6 % |
| 2024 | 2.5 m | -2.0 m | -77.3 % | +670.5 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by THX Pharma over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 12.5 m | 9.1 m | 4.9 m | 966,589 | 7.8 m |
| Total Debt | 5.3 m | 4.9 m | 3.6 m | 2.9 m | 2.9 m |
| Net Debt | -192,753 | 2.8 m | 2.4 m | 2.2 m | 2.1 m |
| Equity | 10.2 m | 5.7 m | 2.2 m | -1.7 m | 2.0 m |
| Total assets | 16.9 m | 12.1 m | 7.2 m | 3.7 m | 10.5 m |
| Operating cash flow | -6.2 m | -5.4 m | -6.4 m | -3.4 m | -883,758 |
| Investments (capex) | 150,618 | 41,219 | 43,608 | 32,723 | 257,228 |
| Free cash-flow | -6.4 m | -5.4 m | -6.4 m | -3.4 m | -939,810 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
THX Pharma compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| THX Pharma | 53.4 m | n/a | 0.0 % |
| Poxel S.A. POXEL.PA | 9.9 m | n/a | n/a |
| Ikonisys S.A. ALIKO.PA | 25.1 m | n/a | -302.8 % |
| Aelis Farma S.A. AELIS.PA | 11.0 m | n/a | -308.7 % |
| NFL Biosciences S.A. ALNFL.PA | 5.7 m | n/a | 0.0 % |
| Valbiotis S.A. ALVAL.PA | 24.9 m | n/a | -1,040.5 % |
| Intrasense S.A. ALINS.PA | 12.1 m | n/a | -364.8 % |
| GenSight Biologics S.A. SIGHT.PA | 14.1 m | n/a | -1,203,600.0 % |
| Predilife S.A. ALPRE.PA | 3.7 m | n/a | -315.3 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in THX Pharma.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 31/10/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about THX Pharma
What is the THX Pharma share price?
Latest recorded price: 3.20 EUR on 06/11/2026, for a market cap of 51.5 m USD.
What is the revenue of THX Pharma?
2.5 m USD for fiscal year 2024, with net income of -2.0 m USD (net margin -77.3 %).
Is THX Pharma stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN FR0013286259) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does THX Pharma have?
12 full-time employees according to the latest published profile.
Who runs THX Pharma?
Mathieu Bernard Mari Charveriat is the company's chief executive.